Moran Wealth Management LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 100.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,434 shares of the medical research company’s stock after purchasing an additional 40,217 shares during the quarter. Moran Wealth Management LLC’s holdings in IQVIA were worth $13,717,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its stake in IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares in the last quarter. Geode Capital Management LLC lifted its stake in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after buying an additional 24,453 shares in the last quarter. Boston Partners lifted its stake in IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after buying an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after buying an additional 528,753 shares during the period. Finally, Alliancebernstein L.P. increased its position in shares of IQVIA by 1.2% during the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after acquiring an additional 41,643 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on IQV. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Evercore reaffirmed an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and increased their target price for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, HSBC set a $210.00 price objective on IQVIA in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $222.00.
IQVIA Trading Down 0.3%
Shares of NYSE:IQV opened at $206.38 on Friday. The company’s 50-day moving average price is $176.95 and its two-hundred day moving average price is $189.30. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a market capitalization of $34.44 billion, a PE ratio of 25.57, a price-to-earnings-growth ratio of 1.78 and a beta of 1.20.
IQVIA (NYSE:IQV – Get Free Report) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the business earned $2.70 earnings per share. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.
IQVIA announced that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Recommended Stories
- Five stocks we like better than IQVIA
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
